Seres Therapeutics   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Cambridge MA United States (2010)

Organization Overview

First Clinical Trial
2015
NCT02437487
First Marketed Drug
2023
fecal microbiota spores, live-brpk (Vowst)
First NDA Approval
2023
fecal microbiota spores, live-brpk (Vowst)
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Seres Therapeutics, Inc.

Active Ingredients

Marketed Drugs (1)

fecal microbiota spores, live-brpk (Vowst) (2023 NDA)

Drugs in Phase 3 Trials (1)

Firmicutes spores (4 trials)

Drugs in Phase 2 Trials (2)

ser-287 (2 trials)

vancomycin (Vancocin) (4 trials)

Drugs in Phase 1 Trials (4)

nivolumab (opdivo) (1 trial)

ser-155 (1 trial)

ser-262 (1 trial)

ser-401 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Clostridium Infections (Phase 3)

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Communicable Diseases (Phase 3)

Infections (Phase 3)

Melanoma (Phase 1)

Recurrence (Phase 1)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 7